Literature DB >> 30370427

AR-V7 and treatment selection in advanced prostate cancer: are we there yet?

Diogo A Bastos1, Emmanuel S Antonarakis2.   

Abstract

Entities:  

Year:  2018        PMID： 30370427      PMCID： PMC6201248          DOI： 10.21037/pcm.2018.09.01

Source DB:  PubMed          Journal:  Precis Cancer Med        ISSN： 2617-2216


× No keyword cloud information.
  13 in total

1.  Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer.

Authors:  Howard I Scher; Ryon P Graf; Nicole A Schreiber; Anuradha Jayaram; Eric Winquist; Brigit McLaughlin; David Lu; Martin Fleisher; Sarah Orr; Lori Lowes; Amanda Anderson; Yipeng Wang; Ryan Dittamore; Alison L Allan; Gerhardt Attard; Glenn Heller
Journal:  JAMA Oncol       Date:  2018-09-01       Impact factor: 31.777

2.  Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis.

Authors:  Heng Li; Zhize Wang; Kun Tang; Hui Zhou; Haoran Liu; Libin Yan; Wei Guan; Ke Chen; Hua Xu; Zhangqun Ye
Journal:  Eur Urol Focus       Date:  2017-01-23

3.  Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic.

Authors:  Himisha Beltran; Emmanuel S Antonarakis; Michael J Morris; Gerhardt Attard
Journal:  Am Soc Clin Oncol Educ Book       Date:  2016

Review 4.  Metastatic Prostate Cancer.

Authors:  Oliver Sartor; Johann S de Bono
Journal:  N Engl J Med       Date:  2018-02-07       Impact factor: 91.245

5.  Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.

Authors:  Emmanuel S Antonarakis; Changxue Lu; Brandon Luber; Hao Wang; Yan Chen; Mary Nakazawa; Rosa Nadal; Channing J Paller; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Jun Luo
Journal:  JAMA Oncol       Date:  2015-08       Impact factor: 31.777

6.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

Authors:  Emmanuel S Antonarakis; Changxue Lu; Hao Wang; Brandon Luber; Mary Nakazawa; Jeffrey C Roeser; Yan Chen; Tabrez A Mohammad; Yidong Chen; Helen L Fedor; Tamara L Lotan; Qizhi Zheng; Angelo M De Marzo; John T Isaacs; William B Isaacs; Rosa Nadal; Channing J Paller; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Jun Luo
Journal:  N Engl J Med       Date:  2014-09-03       Impact factor: 91.245

7.  Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.

Authors:  M Nakazawa; C Lu; Y Chen; C J Paller; M A Carducci; M A Eisenberger; J Luo; E S Antonarakis
Journal:  Ann Oncol       Date:  2015-06-27       Impact factor: 32.976

8.  Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.

Authors:  Emmanuel S Antonarakis; Changxue Lu; Brandon Luber; Hao Wang; Yan Chen; Yezi Zhu; John L Silberstein; Maritza N Taylor; Benjamin L Maughan; Samuel R Denmeade; Kenneth J Pienta; Channing J Paller; Michael A Carducci; Mario A Eisenberger; Jun Luo
Journal:  J Clin Oncol       Date:  2017-04-06       Impact factor: 44.544

9.  Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells.

Authors:  Wendy Onstenk; Anieta M Sieuwerts; Jaco Kraan; Mai Van; Annemieke J M Nieuweboer; Ron H J Mathijssen; Paul Hamberg; Hielke J Meulenbeld; Bram De Laere; Luc Y Dirix; Robert J van Soest; Martijn P Lolkema; John W M Martens; Wytske M van Weerden; Guido W Jenster; John A Foekens; Ronald de Wit; Stefan Sleijfer
Journal:  Eur Urol       Date:  2015-07-15       Impact factor: 20.096

10.  Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.

Authors:  Howard I Scher; David Lu; Nicole A Schreiber; Jessica Louw; Ryon P Graf; Hebert A Vargas; Ann Johnson; Adam Jendrisak; Richard Bambury; Daniel Danila; Brigit McLaughlin; Justin Wahl; Stephanie B Greene; Glenn Heller; Dena Marrinucci; Martin Fleisher; Ryan Dittamore
Journal:  JAMA Oncol       Date:  2016-11-01       Impact factor: 31.777
View more
  5 in total

1.  Circulating tumor cell-based or tissue biopsy-based AR-V7 detection: which provides the greatest clinical utility?

Authors:  Arpit Rao; Emmanuel S Antonarakis
Journal:  Ann Transl Med       Date:  2019-12

2.  Considerations for AR-V7 testing in clinical routine practice.

Authors:  Christof Bernemann; Laura-Maria Krabbe; Andres Jan Schrader
Journal:  Ann Transl Med       Date:  2019-12

3.  Resistance Mechanisms to Taxanes and PARP Inhibitors in Advanced Prostate Cancer.

Authors:  Alan P Lombard; Allen C Gao
Journal:  Curr Opin Endocr Metab Res       Date:  2020-02-19

Review 4.  Optimizing outcomes for patients with metastatic prostate cancer: insights from South East Asia Expert Panel.

Authors:  Fabio Augusto Barros Schutz; Ekaphop Sirachainan; Shanggar Kuppusamy; Nguyen Thi Thai Hoa; Thitiya Dejthevaporn; Badrulhisham Bahadzor; Vu Quang Toan; Phichai Chansriwong; Adlinda Alip; Nguyen Thi Minh Hue; Napa Parinyanitikul; Ai Lian Tan; Vu Dinh Khanh Hoang; Piyawan Tienchaiananda; Sai Naga Deepak Chinchapattanam; Amit Garg
Journal:  Ther Adv Med Oncol       Date:  2021-02-23       Impact factor: 8.168

5.  AR-V7 as a Biomarker for Resistance to Treatment with Abiraterone/Enzalutamide in Three Latin American Countries: A Hypothetical Cost-Saving Analysis.

Authors:  Rafael Adrián Pacheco-Orozco; Lorena Montealegre-Páez; Federico Cayol; Héctor Martínez-Gregorio; Javier Oliver; Cecilia Frecha; Felipe Vaca-Paniagua; Sandra Perdomo
Journal:  Oncologist       Date:  2020-08-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.